In the MC-38 tumor-bearing mouse model, FGR overexpression negated the suppressive impact of atezolizumab (Fig. 8C, Fig. S7A), supporting the notion that CD8+ T cell deficits within the tumor milieu limit immunotherapeutic outcomes in CRC. This evidence concerns the gene FGR and neoplasm.